Cancer immunotherapy as a new treatment option

Cancer can coaptate the immune control of the immune system (IS), evade immunity and its destruction. So, could we say openly that immunotherapy is a viable treatment option for patients with advanced cancer? Yes, immunotherapy would give us great advances in the war against cancer. Therefore, the development of a new generation of immune modulators (which have been analyzed in the following article) is necessary. In addition, these will be more effective if we use them in combination, taking advantage of their synergy.Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech

Prenatal Diagnosis of Neu–Laxova Syndrome

Neu–Laxova syndrome is a rare and lethal genetic disease with autosomal recessive inheritance involving abnormalities of multiple systems. It was first reported in 1971. Since then, just eighty-eight cases have been reported. The syndrome is characterized by early and severe growth restriction, and craniofacial anomalies, such as microcephaly, hypertelorism and other malformations, resulting in quite characteristic features. Additionally, it might appear as generalized edema, flexion contractures and other malformations of the extremities, abnormalities in the CNS (central nervous system), skin (severe ichthyosis), and genitourinary and cardiac abnormalities. We present the case of a patient who had her first pregnancy with a fetus with Neu–Laxova syndrome diagnosed in our center during the second-trimester ultrasound. The ultrasound findings suggested the diagnosis, which was confirmed with a genetic study of the amniotic fluid: the variant of the PSAT1 gene, associated with NLS (Neu–Laxova syndrome) 2 in homozygosis. Moreover, there was a second pregnancy with a fetus carrying the same mutation in heterozygosis. In addition, we have carried out a review of published literature about this disease up to the present time